{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:03:47Z","timestamp":1784952227935,"version":"3.55.0"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013394","name":"Instituto Nacional de Medicina Gen\u00f3mica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003141","name":"Consejo Nacional de Ciencia y Tecnolog\u00eda","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003141","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:p>Recent studies suggest that the endocannabinoid system could play an important role in the physiopathology of obsessive-compulsive disorder (OCD). There are reports of effective treatment with derivatives of tetrahydrocannabinol (THC). The study of the genetic factor associated with psychiatric disorders has made possible an exploration of its contribution to the pharmacological response. However, very little is known about the genetic factor or the prevalence of cannabis use in the Mexican population with OCD. The objective of this study is to compare the prevalence of use and dependence on cannabis in individuals with obsessive-compulsive symptomatology (OCS) with that of individuals with other psychiatric symptoms (psychosis, depression, and anxiety), and to explore the association between genetic risk and use. The study includes a total of 13,130 individuals evaluated in the second stage of the 2016 National Survey of Drug, Alcohol, and Tobacco Use (Encodat 2016), with genetic analysis (polygenic risk scoring) of a subsample of 3,521 individuals. Obsessive symptomatology had a prevalence of 7.2% and compulsive symptomatology a prevalence of 8.6%. The proportion of individuals with OCS who had ever used cannabis was 23.4%, and of those with cannabis dependency was 2.7%, the latter figure higher than that in individuals with other psychiatric symptoms (hypomania, 2.6%; anxiety, 2.8%; depression, 2.3%), except psychosis (5.9%). Individuals with OCS who reported using cannabis had an increased genetic risk for cannabis dependence but not for OCD. We thus cannot know how the increased genetic risk of cannabis dependence in people with OCD is influenced by their pharmacological response to derivatives of THC. The results, however, suggest paths for future studies.<\/jats:p>","DOI":"10.3389\/fpsyt.2021.664228","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T05:48:26Z","timestamp":1620625706000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Cannabis Use in People With Obsessive-Compulsive Symptomatology: Results From a Mexican Epidemiological Sample"],"prefix":"10.3389","volume":"12","author":[{"given":"Humberto","family":"Nicolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Jaime","family":"Mart\u00ednez-Maga\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alma Delia","family":"Genis-Mendoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Ameth","family":"Villatoro Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Camarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Fleiz Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marycarmen","family":"Bustos-Gami\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Aguilar Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Lanzagorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Elena","family":"Medina-Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive-compulsive disorder in the national comorbidity survey replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s00127-012-0507-8","article-title":"Obsessive-compulsive disorder: prevalence, correlates, help-seeking and quality of life in a multiracial asian population","volume":"47","author":"Subramaniam","year":"2012","journal-title":"Soc Psychiatry Psychiatr Epidemiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pnpbp.2005.11.001","article-title":"The descriptive epidemiology of obsessive-compulsive disorder","volume":"30","author":"Fontenelle","year":"2006","journal-title":"Prog Neuro-Psychopharmacology Biol Psychiatry."},{"key":"B4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1002\/da.20669","article-title":"Obsessive-compulsive disorder: a review of the diagnostic criteria possible subtypes dimensional specifiers for DSM-V","volume":"27","author":"Leckman","year":"2010","journal-title":"Depress Anxiety."},{"key":"B5","unstructured":"Serotonin transporter gene polymorphisms & obsessive-compulsive disorder663665\n            NicoliniH\n          Indian J Med Res.1322010"},{"key":"B6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fpsyt.2011.00070","article-title":"Obsessive\u2013compulsive disorder comorbidity: clinical assessment and therapeutic implications","volume":"2","author":"Pallanti","year":"2011","journal-title":"Front Psychiatry."},{"key":"B7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-019-0102-3","article-title":"Obsessive\u2013compulsive disorder","volume":"5","author":"Stein","year":"2019","journal-title":"Nat Rev Dis Prim."},{"key":"B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/ajmg.b.32777","article-title":"Genetic meta-analysis of obsessive\u2013compulsive disorder and self-report compulsive symptoms","volume":"183","author":"Smit","year":"2020","journal-title":"Am J Med Genet Part B Neuropsychiatr Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.4103\/psychiatry.IndianJPsychiatry_525_18","article-title":"Neuroimaging findings in obsessive-compulsive disorder: a narrative review to elucidate neurobiological underpinnings","volume":"61","author":"Hazari","year":"2019","journal-title":"Indian J Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1053\/scnp.2001.21833","article-title":"Brain-behavior relationships in obsessive-compulsive disorder","volume":"6","author":"Saxena","year":"2001","journal-title":"Semin Clin Neuropsychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pscychresns.2004.07.001","article-title":"A meta-analysis of functional neuroimaging in obsessive-compulsive disorder","volume":"132","author":"Whiteside","year":"2004","journal-title":"Psychiatry Res Neuroimaging."},{"key":"B12","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1089\/can.2018.0049","article-title":"The endocannabinoid system: a New treatment target for obsessive compulsive disorder?","volume":"4","author":"Kayser","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.neuropharm.2012.06.063","article-title":"Cannabinoid facilitation of fear extinction memory recall in humans","volume":"64","author":"Rabinak","year":"2013","journal-title":"Neuropharmacology."},{"key":"B14","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.nlm.2013.09.009","article-title":"Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans","volume":"113","author":"Rabinak","year":"2014","journal-title":"Neurobiol Learn Mem."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/j.biopsych.2015.06.008","article-title":"An overview of translationally informed treatments for posttraumatic stress disorder: animal models of pavlovian fear conditioning to human clinical trials","volume":"78","author":"Bowers","year":"2015","journal-title":"Biol Psychiatry."},{"key":"B16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1038\/nrn4036","article-title":"The endocannabinoid system in guarding against fear, anxiety and stress","volume":"16","author":"Lutz","year":"2015","journal-title":"Nat Rev Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpsyt.2020.00681","article-title":"Cannabis improves obsessive-compulsive disorder\u2014Case report and review of the literature","volume":"11","author":"Szejko","year":"2020","journal-title":"Front Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11481-018-9782-9","article-title":"Cannabis addiction and the brain: a review","volume":"13","author":"Zehra","year":"2018","journal-title":"J Neuroimmune Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/add.14776","article-title":"Heavy cannabis use, dependence and the brain: a clinical perspective","volume":"115","author":"Kroon","year":"2020","journal-title":"Addiction."},{"key":"B20","doi-asserted-by":"publisher","first-page":"107621","DOI":"10.1016\/j.drugalcdep.2019.107621","article-title":"Cannabis use disorder among people using cannabis daily\/almost daily in the united states, 2002\u201320","volume":"205","author":"Santaella-Tenorio","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"B21","doi-asserted-by":"publisher","first-page":"E339","DOI":"10.9778\/cmajo.20180023","article-title":"The adverse health effects and harms related to marijuana use: an overview review","volume":"6","author":"Memedovich","year":"2018","journal-title":"C Open."},{"key":"B22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00406-018-0970-7","article-title":"Cannabis and mental illness: a review","volume":"269","author":"Lowe","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41593-018-0206-1","article-title":"GWAS of lifetime cannabis use reveals new risk loci, genetic overlap with psychiatric traits, and a causal influence of schizophrenia","volume":"21","author":"Pasman","year":"2018","journal-title":"Nat Neurosci."},{"key":"B24","unstructured":"El consumo de drogas en m\u00e9xico: resultados de la encuesta nacional de adicciones44757\n            VillatoroJ\n            Medina-MoraME\n            Fleiz BautistaC\n            MorenoL\u00f3pez M\n            RoblesNO\n            BustosGami\u00f1o M\n          10.17711\/SM.0185-3325.2012.001352012"},{"key":"B25","doi-asserted-by":"publisher","first-page":"294","DOI":"10.20882\/adicciones.29","article-title":"The drug scene in mexico and the road ahead","volume":"25","author":"Medina-Mora","year":"2013","journal-title":"Adicciones."},{"key":"B26","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ajmg.b.32160","article-title":"The genomic psychiatry cohort: partners in discovery","author":"Pato","year":"2013","journal-title":"Am J Med Genet B Neuropsychiatr Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.schres.2015.02.013","article-title":"Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT","volume":"164","author":"Docherty","year":"2015","journal-title":"Schizophr Res."},{"key":"B28","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jamapsychiatry.2013.3726","article-title":"Comorbidity of severe psychotic disorders with measures of substance use","volume":"71","author":"Hartz","year":"2014","journal-title":"JAMA Psychiatry."},{"key":"B29","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e1608","DOI":"10.1002\/mpr.1608","article-title":"A tutorial on conducting genome-wide association studies: quality control and statistical analysis","volume":"27","author":"Marees","year":"2018","journal-title":"Int J Methods Psychiatr Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/gepi.21896","article-title":"Robust inference of population structure for ancestry prediction and correction of stratification in the presence of relatedness","volume":"39","author":"Conomos","year":"2015","journal-title":"Genet Epidemiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nrg1596","article-title":"The human genome diversity project: past, present and future","volume":"6","author":"Cavalli-Sforza","year":"2005","journal-title":"Nat Rev Genet."},{"key":"B33","unstructured":"Medicinal cannabis: history, pharmacology, and implications for the acute care setting1801\n            BridgemanMB\n            AbaziaDT\n          28250701P T.422017"},{"key":"B34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1186\/s13643-019-1243-x","article-title":"Benefits and harms of medical cannabis: a scoping review of systematic reviews","volume":"8","author":"Pratt","year":"2019","journal-title":"Syst Rev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"45","DOI":"10.2147\/DHPS.S158592","article-title":"Therapeutic potential of medicinal marijuana: an educational primer for health care professionals","volume":"10","author":"Mouhamed","year":"2018","journal-title":"Drug Healthc Patient Saf."},{"key":"B36","unstructured":"Therapeutic effects of cannabis and cannabinoidsWashington, DCNational Academies PressThe Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research2017"},{"key":"B37","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1155\/2013\/294264","article-title":"Treatment of tourette syndrome with cannabinoids","volume":"27","author":"M\u00fcller-Vahl","year":"2013","journal-title":"Behav Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/sj.npp.1300047","article-title":"Treatment of tourette syndrome with delta-9-tetrahydrocannabinol (\u03949-THC): no influence on neuropsychological performance","volume":"28","author":"M\u00fcller-Vahl","year":"2003","journal-title":"Neuropsychopharmacology."},{"key":"B39","doi-asserted-by":"publisher","first-page":"459","DOI":"10.4088\/JCP.v64n0417","article-title":"\u03949-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: A 6-week randomized trial","volume":"64","author":"M\u00fcller-Vahl","year":"2003","journal-title":"J Clin Psychiatry."},{"key":"B40","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2018.07.010","article-title":"Differential relationships of PTSD and childhood trauma with the course of substance use disorders","volume":"93","author":"Mergler","year":"2018","journal-title":"J Subst Abuse Treat."},{"key":"B41","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3389\/fpsyt.2019.00063","article-title":"The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder","volume":"10","author":"Chye","year":"2019","journal-title":"Front Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1038\/s41386-018-0050-8","article-title":"Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle","volume":"43","author":"Gonzalez-Cuevas","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"B43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1097\/JCP.0000000000001179","article-title":"Cannabinoid augmentation of exposure-Based psychotherapy for obsessive-compulsive disorder","volume":"40","author":"Kayser","year":"2020","journal-title":"J Clin Psychopharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/phar.1747","article-title":"Treatment of cannabis use disorder: current science and future outlook","volume":"36","author":"Sherman","year":"2016","journal-title":"Pharmacotherapy."},{"key":"B45","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00406-019-01068-z","article-title":"Cannabis use and psychosis: a review of reviews","volume":"270","author":"Hasan","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"S494","DOI":"10.4103\/psychiatry.IndianJPsychiatry_18_18","article-title":"Psychosocial interventions in patients with dual diagnosis","volume":"60","author":"Subodh","year":"2018","journal-title":"Indian J Psychiatry."},{"key":"B47","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-244X-14-136","article-title":"A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- a meta-analysis of 31 studies","volume":"14","author":"Kedzior","year":"2014","journal-title":"BMC Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13293-018-0182-x","article-title":"The association between cannabis use and suicidal behavior in patients with psychiatric disorders: an analysis of sex differences","volume":"9","author":"Naji","year":"2018","journal-title":"Biol Sex Differ."},{"key":"B49","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/add.13557","article-title":"Trajectories of cannabis use disorder: risk factors, clinical characteristics and outcomes","volume":"112","author":"Kosty","year":"2017","journal-title":"Addiction."},{"key":"B50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s40429-017-0133-3","article-title":"Longitudinal studies on the etiology of cannabis use disorder: a review","volume":"4","author":"Courtney","year":"2017","journal-title":"Curr Addict Reports."},{"key":"B51","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1177\/0706743718804541","article-title":"Early risk factors for daily cannabis use in young adults","volume":"64","author":"Dugas","year":"2019","journal-title":"Can J Psychiatry."},{"key":"B52","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13073-017-0489-y","article-title":"Prospects for using risk scores in polygenic medicine","volume":"9","author":"Lewis","year":"2017","journal-title":"Genome Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/jamapsychiatry.2020.3049","article-title":"From basic science to clinical application of polygenic risk scores: a primer","volume":"78","author":"Wray","year":"","journal-title":"JAMA Psychiatry"},{"key":"B54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1001\/jamapsychiatry.2020.3042","article-title":"Could polygenic risk scores be useful in psychiatry? a review","volume":"78","author":"Murray","year":"","journal-title":"JAMA Psychiatry"},{"key":"B55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.neubiorev.2020.11.021","article-title":"Polygenic risk scores for genetic counseling in psychiatry: lessons learned from other fields of medicine","volume":"121","author":"Eeltink","year":"","journal-title":"Neurosci Biobehav Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e1008060","DOI":"10.1371\/journal.pgen.1008060","article-title":"On the utilization of polygenic risk scores for therapeutic targeting","volume":"15","author":"Gibson","year":"2019","journal-title":"PLoS Genet."},{"key":"B57","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41398-018-0230-7","article-title":"Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort","volume":"8","author":"Santoro","year":"2018","journal-title":"Transl Psychiatry."},{"key":"B58","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1176\/appi.ajp.2018.17121363","article-title":"Schizophrenia polygenic risk score as a predictor of antipsychotic efficacy in first-episode psychosis","volume":"176","author":"Zhang","year":"2019","journal-title":"Am J Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jad.2013.03.014","article-title":"Clinical relevance of comorbidity in obsessive compulsive disorder: the netherlands oCD association study","volume":"150","author":"Hofmeijer-Sevink","year":"2013","journal-title":"J Affect Disord."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.664228\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T05:48:31Z","timestamp":1620625711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2021.664228\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":59,"alternative-id":["10.3389\/fpsyt.2021.664228"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2021.664228","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"article-number":"664228"}}